文献速递肿瘤 PET/CT核素与放射性配体治疗

改进肿瘤滞留的成纤维细胞激活蛋白靶向放射性示踪剂研发

Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.
PubMed 文献 · J Nucl Med · 2019-03-08

研究合成新型喹啉类FAP靶向放射性示踪剂,在HT-1080-FAP细胞和小鼠模型中评估结合与显像性能,多数衍生物较FAPI-04结合与肿瘤摄取改善;FAPI-21和FAPI-46在8例癌症患者PET显像中给药后10分钟即见高肿瘤摄取,FAPI-21在口腔黏膜、唾液腺和甲状腺摄取更高。

要点

  • 15个FAPI衍生物中11个体外FAP结合优于FAPI-04,7个小鼠肿瘤摄取增加。
  • FAPI-21和FAPI-46显著改善肿瘤与血液、肝、肌肉、肠道摄取比值。
  • 8例患者中FAPI-21和FAPI-46给药后10分钟即高肿瘤摄取,FAPI-21正常组织摄取更高。

核心结论

  • 化学修饰FAPI框架可增强FAP结合并改善多数衍生物药代动力学,获得高对比度图像。
  • 更高放射性剂量可在减少健康组织损伤的同时给药,可能改善治疗结果。

研究设计与样本

  • 研究经有机化学合成新型喹啉类放射性示踪剂,用FAP表达HT-1080细胞行放射性配体结合试验。
  • 根据体外性能,在HT-1080-FAP荷瘤小鼠行小动物PET显像和生物分布研究。
  • 最有前景化合物用于8例癌症患者临床PET显像。

主要发现

  • 与FAPI-04相比,15个FAPI衍生物中11个体外FAP结合改善。
  • 上述衍生物中7个在荷瘤小鼠肿瘤摄取增加。
  • 多数化合物肿瘤与正常器官比值改善,图像对比度更高。
  • FAPI-21和FAPI-46的肿瘤与血液、肝、肌肉、肠道摄取比值显著改善。
  • 8例患者中FAPI-21和FAPI-46给药后10分钟即见高瘤内摄取,FAPI-21在口腔黏膜、唾液腺和甲状腺摄取更高。

临床怎么用

  • FAPI-21和FAPI-46在患者中给药后10分钟即高肿瘤摄取,可用于诊断性PET显像。
  • FAPI-21正常口腔黏膜、唾液腺和甲状腺摄取更高,临床选用时需考虑。
  • 改进的肿瘤滞留和对比度可能支持更高放射性剂量治疗应用。

局限性

  • 临床PET显像仅8例癌症患者,样本量有限。
  • 原文未报告诊断准确性、剂量学或治疗疗效数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer-associated fibroblasts constitute a vital subpopulation of the tumor stroma and are present in more than 90% of epithelial carcinomas. The overexpression of the serine protease fibroblast activation protein (FAP) allows a selective targeting of a variety of tumors by inhibitor-based radiopharmaceuticals (FAPIs). Of these compounds, FAPI-04 has been recently introduced as a theranostic radiotracer and demonstrated high uptake into different FAP-positive tumors in cancer patients. To enable the delivery of higher doses, thereby improving the outcome of a therapeutic application, several FAPI variants were designed to further increase tumor uptake and retention of these tracers. Methods: Novel quinoline-based radiotracers were synthesized by organic chemistry and evaluated in radioligand binding assays using FAP-expressing HT-1080 cells. Depending on their in vitro performance, small-animal PET imaging and biodistribution studies were performed on HT-1080-FAP tumor-bearing mice. The most promising compounds were used for clinical PET imaging in 8 cancer patients. Results: Compared with FAPI-04, 11 of 15 FAPI derivatives showed improved FAP binding in vitro. Of these, 7 compounds demonstrated increased tumor uptake in tumor-bearing mice. Moreover, tumor-to-normal-organ ratios were improved for most of the compounds, resulting in images with higher contrast. Notably two of the radiotracers, FAPI-21 and -46, displayed substantially improved ratios of tumor to blood, liver, muscle, and intestinal uptake. A first diagnostic application in cancer patients revealed high intratumoral uptake of both radiotracers already 10 min after administration but a higher uptake in oral mucosa, salivary glands, and thyroid for FAPI-21. Conclusion: Chemical modification of the FAPI framework enabled enhanced FAP binding and improved pharmacokinetics in most of the derivatives, resulting in high-contrast images. Moreover, higher doses of radioactivity can be delivered while minimizing damage to healthy tissue, which may improve therapeutic outcome.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Loktev A, Lindner T, Burger EM, et al. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention. J Nucl Med. 2019. PMID: 30850501. doi:10.2967/jnumed.118.224469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。